Deep Stock Research
XV
Majority Opinion (5 of 7 members)

Equifax occupies one of the most structurally advantaged positions in American business — one of only three consumer credit bureaus in the United States, operating in a regulated oligopoly where no new entrant has gained meaningful scale in decades. The business generates $6.1 billion in revenue with 56% gross margins and $1.06 billion in free cash flow, serving as a mandatory data checkpoint for virtually every consumer lending, insurance underwriting, and employment verification decision in the country. Revenue has compounded at 7.6% annually over ten years, and the cloud transformation that depressed margins and consumed capital through 2023 is now yielding tangible results: capex has declined from $601 million in 2023 to $481 million in 2025, and FCF has surged from $239 million to $1.06 billion over the same period. However, the majority is not ready to buy at $169.50 due to three interconnected concerns. First, return on invested capital has declined from 13% in 2015 to approximately 8% today — a troubling trajectory for a supposed oligopoly that suggests the massive cloud transformation capex has not yet translated into superior economic returns. Second, the balance sheet carries $6.15 billion in total debt against just $286 million in cash, producing net debt of $5.87 billion or 3.2x EBITDA. Management returned $1.16 billion to shareholders in FY2025 through dividends and buybacks — exceeding the $1.06 billion in free cash flow by roughly $100 million, with total debt increasing by $427 million year-over-year. This pattern of returning more than the business generates while adding leverage is unsustainable. Third, the stock trades at approximately 31x trailing earnings and 14.7x EV/EBITDA, which prices in substantial margin recovery and growth acceleration that has not yet materialized in the reported numbers. Our blended fair value of $175–$180 is derived from three approaches: (1) 15x normalized EBITDA of $1.815 billion yields an enterprise value of $27.2 billion, minus $5.87 billion net debt, divided by 120 million shares equals $178 per share; (2) 28x normalized EPS of $6.00 (assuming modest margin improvement) equals $168; (3) 18x FCF per share of $8.84 equals $159, though we adjust upward to $175 recognizing FCF is still ramping post-cloud migration. Averaging these approaches yields approximately $175. We would begin accumulating at $145–$150, which provides a 15–17% margin of safety and a more attractive FCF yield of approximately 6.0%. Patience is warranted as the cloud transformation benefits must prove out in ROIC improvement before we pay a premium multiple.

Minority Dissent (2 of 7 members)

The minority views Equifax at $169.50 as a compelling entry point for one of America's most structurally inevitable data businesses. Dev Kantesaria sees Equifax as a core toll booth holding: every mortgage application, every credit card decision, every tenant screening, every employment verification flows through one of three credit bureaus, and Equifax's proprietary datasets — particularly The Work Number payroll database — are irreplaceable. The cloud transformation that depressed margins and consumed capital is now in the rearview mirror, with capex declining and FCF surging from $239M to $1.06B in just two years. The market is offering this business at a 5.1% FCF yield on a capital structure that is rapidly deleveraging through normalized cash generation. David Tepper sees the asymmetric catalyst setup: mortgage origination volumes are at cyclically depressed levels, representing 20% of revenue with significant operating leverage on recovery. Management explicitly stated they grew revenue 7% even with mortgage down 7% and hiring down 2% — meaning the base business is growing at high single digits before any cyclical recovery. If mortgage volumes normalize, incremental revenue drops at near-100% margins through the cloud platform, creating a 20-30% earnings upside scenario. At 31x trailing but roughly 24-25x two-year forward earnings, the risk-reward favors buying now rather than waiting for a pullback that may not materialize as the cyclical recovery unfolds.